Article Details

New Company Debuts with $72 Million to Advance a Novel Class of Targeted Radiopharmaceuticals

Retrieved on: 2021-03-18 11:36:38

Tags for this article:

Click the tags to see associated articles and topics

New Company Debuts with $72 Million to Advance a Novel Class of Targeted Radiopharmaceuticals. View article details on hiswai:

Excerpt

Aktis Oncology's proprietary technology platform harnesses the power of alpha particles. Aktis Oncology's theranostic approach would also enable ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up